Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Utilization of extracts from racemosa rhizoma for producing estrogen-like organ-selective medicament for suppressing LHSP activity

An extract, technology of cohosh, applied in the field of application of cohosh raceme extract in the production of estrogen-type organ-selective drugs for inhibiting luteinizing hormone activity, which can solve problems such as unrealization

Inactive Publication Date: 2010-01-20
BIONORICA AG
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Discomfortably, however, such phytomedicines, which could have been used so far for organ-selective prophylaxis or treatment in estrogen-deficient conditions, were not possible with the current state of the art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Utilization of extracts from racemosa rhizoma for producing estrogen-like organ-selective medicament for suppressing LHSP activity
  • Utilization of extracts from racemosa rhizoma for producing estrogen-like organ-selective medicament for suppressing LHSP activity
  • Utilization of extracts from racemosa rhizoma for producing estrogen-like organ-selective medicament for suppressing LHSP activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0057] Example: With reference to the technique of Harms and Ojeda (Harms PG; Ojeda SR: a rapid and simple operation of chronic intubation of rat jugular vein. J.Appl.Physiol. (1974) 36:391-392), the catheter Placed in the external jugular vein of OVX rats anesthetized with ethyl ether 24 hours before the start of the experiment. Place one end of the tube in a pocket of skin in the neck. In order not to touch the animal while taking blood samples, extend the catheter with silicone tubing. Both the catheter and the silicone tubing were flushed with Ringer's solution containing 50 IU / ml heparin.

[0058] Blood samples of 100 μl were taken from each animal at 10 min intervals and supplemented with the same volume of Ringer / heparin solution. After the sixth sampling, 1.0 ml of the respective test solution was injected intravenously. The test solutions were: 2% polyethylene glycol compound (=vehicle solution), irisaxanthin (7 mg / ml vehicle), 17-β-estradiol (10 μg / ml vehicle). B...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of extracts from Iridaceae and from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and / or prophylaxis of cardiovascular diseases, in particular atherosclerose, osteoporose and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

Description

[0001] This application was submitted on March 19, 1999, and the Chinese application number is 99804123.8, entitled "Using extracts of Iridaceae and raceme cohosh and iris xanthin as estrogen type has organ selectivity without uterotropism A divisional application for the invention of Drugs with Actions. technical field [0002] The present invention relates to extracts of Cimicifuga racemosa and irisin as estrogen-type organ-selective drugs. Background technique [0003] 17-β-estradiol formed in the ovary (the estradiol mentioned later refers to the physiological 17-β-estradiol) [hereinafter also referred to as E 2 Said] generally promote the proliferation of the organ. In addition to controlling the female (menstrual) cycle, when it is deficient, it has an internal environment stabilizing effect on the metabolism of bones, and also prevents the formation of atherosclerotic plaques in the vascular endothelium. [0004] During menopause, estradiol levels drop due to the ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/35A61K36/00A61P15/12A61P9/10A61P19/10A61K36/71A61K31/352A61K31/7048A61K36/18A61K36/88A61K36/8965A61P9/00G01D5/34
CPCA61K31/352A61K36/88A61K36/71A61P15/12A61P19/10A61P5/30A61P9/00A61P9/10A61K2300/00
Inventor W·武特克H·哈里V·克里斯托夫B·施彭格勒M·波珀
Owner BIONORICA AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com